CRAC and DDR2 Inhibitor Composition for Fibrosis and Cytokine Storms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no optimal therapeutic product specifically targeting calcium release-activated calcium (CRAC) channel-related disorders or discoidin domain receptor 2 (DDR2)-related disorders, leading to unmet needs in treating or preventing conditions such as fibrosis, cytokine storms, and cancer metastasis, which pose significant health burdens.
Innovation Solution
Administering WRG-28 and/or atovaquone (Av), or their precursors, along with pharmaceutically acceptable carriers, to inhibit CRAC channel and/or DDR2 activation, thereby reducing fibroblast activation, collagen deposition, and modulating immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If WRG-28 and/or atovaquone are administered to inhibit CRAC channel and DDR2 activation, then fibrosis is reduced and tissue repair is promoted, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent combines WRG-28 and atovaquone into a single pharmaceutical composition that targets both CRAC channel and DDR2 pathways simultaneously. This merging of multiple therapeutic agents into one formulation maintains comprehensive treatment effectiveness while simplifying the administration regimen for patients.
Solution Approach 2:
The pharmaceutical composition is designed to perform multiple functions: inhibiting CRAC channel activation, inhibiting DDR2 activation, reducing fibrosis, and promoting tissue repair. This multi-functionality allows a single treatment to address multiple aspects of the disease process without requiring separate administrations.
2Reliability
If CRAC channel and DDR2 are inhibited to treat fibrosis and cytokine storms, then organ function is improved, but the risk of off-target effects increases
Solution Approach 1:
The patent employs selective inhibition where WRG-28 specifically targets CRAC channel activation while atovaquone specifically targets DDR2 activation. Each compound acts with localized specificity on its intended molecular target, minimizing off-target effects while achieving comprehensive therapeutic outcomes in fibrotic and inflammatory conditions.
Data Source
AI summary
A method for treating or preventing a calcium release-activated calcium (CRAC) channel related disorder or condition and/or discoidin domain receptor 2 (DDR2) related disorders or conditions includes administering a subject in need thereof with a pharmaceutical composition. Also provided is a method for inhibiting CRAC channel activation and/or DDR2 activation in a cell of a subject, including administering the subject in need thereof with a pharmaceutical composition. The pharmaceutical composition includes an effective amount of at least one selected from the group consisting of WRG-28, atovaquone (Av), WRG-28 precursors, and atovaquone (Av) precursors; and a pharmaceutically acceptable carrier thereof.